ResearcherUniversity Medical Center of the Johannes Gutenberg University MainzActive in the last 2 years

Özlem Türeci

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0623-1497; OpenAlex author ID A5000036560. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 30

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 4

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Uğur Şahin · 3 shared papers, 2019–2025 · strength 0.42
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
- Paper Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immu… DOI 10.1016/j.immuni.2024.04.021 ↗
- Paper Characterization of zolbetuximab in pancreatic cancer models. DOI 10.1080/2162402x.2018.1523096 ↗
Benjamin D. Greenbaum · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Olca Baştürk · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Vinod P. Balachandran · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Taha Merghoub Merghoub · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Ryan Sugarman · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Anna M. Varghese · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Jedd D. Wolchok · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Zachary M. Sethna · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Luis Alfonso Rojas · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Kevin C. Soares · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
T. Peter Kingham · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Akihiro Ohmoto · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Michael Ian D'Angelica · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Ira Mellman · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Wungki Park · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Andrew S. Epstein · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Jeffrey A. Drebin · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Masataka Amisaki · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Elizabeth S. Won · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
William R. Jarnagin · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Alice Chia-Chi Wei · 1 shared paper, 2025 · strength 0.15
- Paper RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. DOI 10.1038/s41586-024-08508-4 ↗
Anna Melissa Schlitter · 1 shared paper, 2024 · strength 0.15
- Paper Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immu… DOI 10.1016/j.immuni.2024.04.021 ↗
Peter J. Bailey · 1 shared paper, 2024 · strength 0.15
- Paper Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immu… DOI 10.1016/j.immuni.2024.04.021 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.